Compounds, pharmaceutical compositions, and methods for inhibiting cyclin-dependent kinases
申请人:——
公开号:US20030220326A1
公开(公告)日:2003-11-27
Pharmaceutical compositions containing effective amounts of CDK-inhibiting diaminothiazole compounds of the following formula (where R
1
and R
2
are as defined in the specification) or their salts, or prodrugs or active metabolites of such compounds or salts, are useful for treating disorders and diseases such as cancer:
1
In preferred embodiments, R
1
and R
2
are independently unsubstituted or substituted carbocyclic or heterocyclic aryl ring structures. Compounds where R
2
is ortho-substituted aryl are especially potent inhibitors of CDKs such as CDK4.
4-Aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases
申请人:AGOURON PHARMACEUTICALS, INC.
公开号:EP1215208B1
公开(公告)日:2006-07-12
4-AMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASES
申请人:AGOURON PHARMACEUTICALS, INC.
公开号:EP1056732B1
公开(公告)日:2006-01-11
US6569878B1
申请人:——
公开号:US6569878B1
公开(公告)日:2003-05-27
[EN] COMPOUNDS FOR TARGETED DEGRADATION OF BRD9<br/>[FR] COMPOSÉS POUR LA DÉGRADATION CIBLÉE DE LA BRD9
申请人:C4 THERAPEUTICS INC
公开号:WO2021178920A1
公开(公告)日:2021-09-10
BRD9 protein degradation compounds or pharmaceutically acceptable salts thereof are provided for the treatment of disorders mediated by BRD9, including but not limited to abnormal cellular proliferation.